IRON-I.C. Trial
Participants serve as their own controls in a two-period crossover design comparing MEX-CD1-supplemented dialysate with standard dialysate. MEX-CD1 is administered at 50 mg/L in CiCa dialysate without dose escalation.
1 sources - 6 claims
Participants serve as their own controls in a two-period crossover design comparing MEX-CD1-supplemented dialysate with standard dialysate. MEX-CD1 is administered at 50 mg/L in CiCa dialysate without dose escalation.